_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated
